Recent News & Research

*March 2022* To build on the advances that have been made in lung cancer over the past several years, researchers have their sights set on improving the efficacy of immunotherapy with novel approaches, the ability to overcome acquired resistance to targeted therapies, and the accessibility to molecular testing and approved…

*March 2022* Adding bevacizumab to the use of erlotinib (Tarceva) in patients with EGFR-mutated non–small cell lung cancer (NSCLC) did not prolong their survival. However, both treatment arms with and without bevacizumab (Avastin) had relatively long survival durations that encouraged researchers, according to study results published in the Lancet. Read more.

*April 2022* In this video, EGFR Resisters co-founder Ivy Elkins does an interview with Rasheda Persinger, MedOnc Nurse Practioner for JADPRO’s Biomarkers in NSCLC Resource Center. It covers how to best discuss biomarker testing, treatments and symptoms with patients diagnosed with lung cancer. Your healthcare team should use clear, understandable…

*February 2022* A growing recognition of the distinct clinical, pathological, and biological features of lung cancers that arise in nonsmokers is fostering greater interest in examining the molecular underpinnings of lung cancer in this patient subset. During the past 2 decades, the treatment of patients with lung cancer has undergone…

*February 2022* The FDA’s Oncologic Drugs Advisory Committee voted against using single-country foreign data to support a biologics license application (BLA) for sintilimab injection plus pemetrexed and platinum-based chemotherapy for the frontline treatment of patients with nonsquamous non–small cell lung cancer (NSCLC). ODAC concluded that supporting data from the phase…

*February 2022*  View the video or read the transcript of expert perspectives on the management of C797S-mutated non–small cell lung cancer following failure of frontline TKIs.

*December 2021* Osimertinib is used to treat a type of lung cancer that has specific changes (mutations) in a gene called EGFR. Although tumors will usually shrink (respond) during treatment with osimertinib, they can stop responding, or become resistant, to osimertinib. A common cause of resistance is ‘MET amplification’, which…